Oragenics INC Form 4 insider transactions

Oragenics Inc. reports that Chief Financial Officer John Spencer was granted employee stock options.

ORAGENICS Director Fred Telling filed an amended Form 4, disclosing a sale of 210 common shares and the grant of 125,000 stock options, while correcting previous beneficial ownership due to a reverse stock split.

ORAGENICS Inc.'s CEO and CFO, Janet Huffman, was granted 250,000 employee stock options with an exercise price of $0.93, vesting over three years.

Natasha Giordano, a Director at ORAGENICS INC, was granted 163,320 stock options as part of her non-employee director compensation program.

ORAGENICS Director Fred Telling reported the sale of 210 common shares and the grant of 125,000 stock options under the company's incentive plan.

Oragenics Director John P. Gandolfo received an immediate grant of 125,000 stock options with an exercise price of $0.93, vesting immediately under the company's equity incentive plan.

Oragenics Inc. Director Alan W. Dunton received an award of 125,000 stock options with an exercise price of $0.93, vesting immediately.

Oragenics Inc. Director Robert C. Koski received an award of 125,000 stock options with an exercise price of $0.93, vesting immediately.

Oragenics Inc. Director Charles L. Pope received an award of 125,000 stock options with an exercise price of $0.93, vesting immediately, under the company's equity incentive plan.

Odyssey Health, Inc., a 10% owner and director of Oragenics Inc. (OGEN), has reported the complete sale of its common stock holdings in the company across two transactions in June 2025.

Odyssey Health, Inc., a 10% owner and director of Oragenics Inc. (OGEN), reported the sale of 10,000 shares of common stock across two transactions in mid-June 2025.

Director Robert Koski converted 1,500,000 shares of Series B Convertible Preferred Stock into 5,000 shares of common stock.

Director Alan Dunton sold 66 shares of Oragenics Inc. common stock at $0.36 per share on December 6, 2024.

Director Fred Telling sold 3,597 shares of Oragenics Inc. at a price of $0.36 per share on December 6, 2024.

Janet Huffman, CFO of Oragenics Inc., reports the acquisition of 80,000 stock options that vest immediately.

J Michael Redmond, President of Oragenics Inc., reports the acquisition of 100,000 employee stock options.

Director Charles Pope acquired 100,000 options of Oragenics Inc. on September 19, 2024, under the company's 2021 Equity Incentive Plan.

Director John Gandolfo receives options to purchase 45,000 shares of Oragenics Inc. common stock.

Director Alan Dunton reports acquisition of options to purchase 65,000 shares of Oragenics Inc. common stock.

Director Robert Koski acquired options to purchase 65,000 shares of Oragenics Inc. common stock on September 19, 2024.

Director Bruce A. Cassidy Sr. received options to purchase 45,000 shares of Oragenics Inc. common stock.

Director Kimberly M. Murphy acquired options to purchase 27,083 shares of Oragenics Inc. common stock on September 19, 2024.

Director Fred Telling acquired 65,000 options in Oragenics Inc. on September 19, 2024, under the company's 2021 Equity Incentive Plan.